GILEAD SCIENCES, INC. (GILD) FY2024 YTD Q3 P&L / Income Statement

Income StatementCash FlowBalance Sheet

Revenue by Product and Service by Geography

2024-01-01 to 2024-09-30

Swipe to see the full flow
GILEAD SCIENCES, INC. (GILD) FY2024 YTD Q3 P&L / Income StatementIncome statement for 2024-01-01 through 2024-09-30. View: Product and Service by Geographical. Revenue uses this breakdown; costs and expenses retain the consolidated categories.SOURCESREVENUE RECONCILIATIONREVENUEGROSSOPERATINGPRE-TAXNETProduct sales - UNITED STATESTotal HIV - UNITED STATESBiktarvy - UNITED STATESProduct sales - EuropeProduct sales - Rest of WorldTotal HIV - EuropeDescovy - UNITED STATESTotal Oncology - UNITED STATESTotal Liver Disease - UNITED STATESBiktarvy - EuropeGenvoya - UNITED STATESTotal HIV - Rest of WorldTotal Oncology - EuropeBiktarvy - Rest of WorldVeklury - UNITED STATESSofosbuvir/Velpatasvir - UNITED STATESOdefsey - UNITED STATESTotal Cell Therapy - UNITED STATESTotal Liver Disease - Rest of WorldTrodelvy - UNITED STATESTotal Cell Therapy - EuropeYescarta - EuropeYescarta - UNITED STATESVeklury - Rest of WorldTotal Liver Disease - EuropeSymtuza - Revenue share - UNITED STATESVemlidy - UNITED STATESVemlidy - Rest of WorldSofosbuvir/Velpatasvir - Rest of WorldTotal Oncology - Rest of WorldTotal Other - UNITED STATESTotal Other - EuropeSofosbuvir/Velpatasvir - EuropeTotal Other - Rest of WorldOdefsey - EuropeTrodelvy - EuropeAmBisome - EuropeVeklury - EuropeTotal Cell Therapy - Rest of WorldTecartus - UNITED STATESAmBisome - Rest of WorldYescarta - Rest of WorldGenvoya - EuropeTecartus - EuropeSymtuza - Revenue share - EuropeTrodelvy - Rest of WorldDescovy - Rest of WorldDescovy - EuropeGenvoya - Rest of WorldRoyalty, contract and other revenues - UNITED STATESRoyalty, contract and other revenues - EuropeAmBisome - UNITED STATESVemlidy - EuropeOdefsey - Rest of WorldTecartus - Rest of WorldSymtuza - Revenue share - Rest of WorldRoyalty, contract and other revenues - Rest of WorldOther - UNITED STATESOther HIV - UNITED STATESOther Liver Disease - EuropeOther Liver Disease - UNITED STATESOther HIV - EuropeOther Liver Disease - Rest of WorldOther - Rest of WorldOther HIV - Rest of WorldOther - EuropeTotal revenuesRevenue before reconciliation (calculated)Components above reported revenue (calculated)Gross profit (calculated)Cost of goods soldOperating income (loss)Operating expenses (calculated)Income (loss) before income taxesOther income (expense), net (calculated)Net income (loss)Income tax (benefit) expenseRevenue before reconciliation (calculated)Revenue beforereconciliation(calculated)$63.36 BGross profit (calculated)Gross profit(calculated)$16.52 BOperating income (loss)Operatingincome (loss)−$790.00 MIncome (loss) before income taxesIncome (loss)before income taxes−$1.48 BTotal revenuesTotal revenues$21.19 BNet income (loss)Net income (loss)−$1.30 BProduct sales - UNITED STATESProduct sales - UNITED STATES$14.96 BOperating expenses (calculated)Operating expenses(calculated)$17.31 BIncome tax (benefit) expenseIncome tax(benefit) expense−$174.00 MTotal HIV - UNITED STATESTotal HIV - UNITED STATES$11.39 BCost of goods soldCost of goods sold$4.67 BBiktarvy - UNITED STATESBiktarvy - UNITED STATES$7.73 BProduct sales - EuropeProduct sales - Europe$3.42 BOther income (expense), net (calculated)Other income,net (calculated)−$687.00 MProduct sales - Rest of WorldProduct sales - Rest of World$2.70 BTotal HIV - EuropeTotal HIV - Europe$1.74 BComponents above reported revenue (calculated)Components abovereported revenue(calculated)−$42.17 BDescovy - UNITED STATESDescovy - UNITED STATES$1.34 BTotal Oncology - UNITED STATESTotal Oncology - UNITED STATES$1.34 BTotal Liver Disease - UNITED STATESTotal Liver Disease - UNITED STATES$1.21 BBiktarvy - EuropeBiktarvy - Europe$1.11 BGenvoya - UNITED STATESGenvoya - UNITED STATES$1.09 BTotal HIV - Rest of WorldTotal HIV - Rest of World$1.04 BTotal Oncology - EuropeTotal Oncology - Europe$828.00 MBiktarvy - Rest of WorldBiktarvy - Rest of World$814.00 MVeklury - UNITED STATESVeklury - UNITED STATES$784.00 MSofosbuvir/Velpatasvir - UNITED STATESSofosbuvir/Velpatasvir- UNITED STATES$737.00 MOdefsey - UNITED STATESOdefsey - UNITED STATES$705.00 MTotal Cell Therapy - UNITED STATESTotal Cell Therapy - UNITED STATES$683.00 MTotal Liver Disease - Rest of WorldTotal Liver Disease - Rest of World$682.00 MTrodelvy - UNITED STATESTrodelvy - UNITED STATES$655.00 MTotal Cell Therapy - EuropeTotal Cell Therapy - Europe$611.00 MYescarta - EuropeYescarta - Europe$509.00 MYescarta - UNITED STATESYescarta - UNITED STATES$502.00 MVeklury - Rest of WorldVeklury - Rest of World$473.00 MTotal Liver Disease - EuropeTotal Liver Disease - Europe$411.00 MSymtuza - Revenue share - UNITED STATESSymtuza - Revenueshare - UNITED STATES$338.00 MVemlidy - UNITED STATESVemlidy - UNITED STATES$338.00 MVemlidy - Rest of WorldVemlidy - Rest of World$328.00 MSofosbuvir/Velpatasvir - Rest of WorldSofosbuvir/Velpatasvir- Rest of World$299.00 MTotal Oncology - Rest of WorldTotal Oncology - Rest of World$280.00 MTotal Other - UNITED STATESTotal Other - UNITED STATES$241.00 MTotal Other - EuropeTotal Other - Europe$236.00 MSofosbuvir/Velpatasvir - EuropeSofosbuvir/Velpatasvir - Europe$230.00 MTotal Other - Rest of WorldTotal Other - Rest of World$228.00 MOdefsey - EuropeOdefsey - Europe$217.00 MTrodelvy - EuropeTrodelvy - Europe$217.00 MAmBisome - EuropeAmBisome - Europe$210.00 MVeklury - EuropeVeklury - Europe$204.00 MTotal Cell Therapy - Rest of WorldTotal Cell Therapy - Rest of World$192.00 MTecartus - UNITED STATESTecartus - UNITED STATES$181.00 MAmBisome - Rest of WorldAmBisome - Rest of World$176.00 MYescarta - Rest of WorldYescarta - Rest of World$170.00 MGenvoya - EuropeGenvoya - Europe$138.00 MTecartus - EuropeTecartus - Europe$102.00 MSymtuza - Revenue share - EuropeSymtuza - Revenue share - Europe$101.00 MTrodelvy - Rest of WorldTrodelvy - Rest of World$88.00 MDescovy - Rest of WorldDescovy - Rest of World$82.00 MDescovy - EuropeDescovy - Europe$75.00 MGenvoya - Rest of WorldGenvoya - Rest of World$66.00 MRoyalty, contract and other revenues - UNITED STATESRoyalty, contract and otherrevenues - UNITED STATES$66.00 MRoyalty, contract and other revenues - EuropeRoyalty, contract andother revenues - Europe$43.00 MAmBisome - UNITED STATESAmBisome - UNITED STATES$37.00 MVemlidy - EuropeVemlidy - Europe$33.00 MOdefsey - Rest of WorldOdefsey - Rest of World$30.00 MTecartus - Rest of WorldTecartus - Rest of World$22.00 MSymtuza - Revenue share - Rest of WorldSymtuza - Revenueshare - Rest of World$9.00 MRoyalty, contract and other revenues - Rest of WorldRoyalty, contract and otherrevenues - Rest of World$2.00 MOther - UNITED STATESOther - UNITED STATES$203.00 MOther HIV - UNITED STATESOther HIV - UNITED STATES$190.00 MOther Liver Disease - EuropeOther Liver Disease - Europe$148.00 MOther Liver Disease - UNITED STATESOther Liver Disease - UNITED STATES$134.00 MOther HIV - EuropeOther HIV - Europe$96.00 MOther Liver Disease - Rest of WorldOther Liver Disease - Rest of World$55.00 MOther - Rest of WorldOther - Rest of World$52.00 MOther HIV - Rest of WorldOther HIV - Rest of World$36.00 MOther - EuropeOther - Europe$26.00 M
Chart details

GILEAD SCIENCES, INC. (GILD) FY2024 YTD Q3 P&L / Income Statement

Income statement for 2024-01-01 through 2024-09-30. View: Product and Service by Geographical. Revenue uses this breakdown; costs and expenses retain the consolidated categories.

Total revenues
21,185,000,000 US dollars
Cost of goods sold
4,670,000,000 US dollars
Gross profit (calculated)
16,515,000,000 US dollars
Operating expenses (calculated)
17,305,000,000 US dollars
Operating income (loss)
negative 790,000,000 US dollars
Other income (expense), net (calculated)
negative 687,000,000 US dollars
Income (loss) before income taxes
negative 1,477,000,000 US dollars
Income tax (benefit) expense
negative 174,000,000 US dollars
Net income (loss)
negative 1,303,000,000 US dollars
Tecartus - UNITED STATES
181,000,000 US dollars
Tecartus - Rest of World
22,000,000 US dollars
Tecartus - Europe
102,000,000 US dollars
Total Cell Therapy - UNITED STATES
683,000,000 US dollars
Total Cell Therapy - Rest of World
192,000,000 US dollars
Total Cell Therapy - Europe
611,000,000 US dollars
Yescarta - UNITED STATES
502,000,000 US dollars
Yescarta - Rest of World
170,000,000 US dollars
Yescarta - Europe
509,000,000 US dollars
Total HIV - UNITED STATES
11,386,000,000 US dollars
Total HIV - Rest of World
1,038,000,000 US dollars
Total HIV - Europe
1,737,000,000 US dollars
Biktarvy - UNITED STATES
7,726,000,000 US dollars
Biktarvy - Rest of World
814,000,000 US dollars
Biktarvy - Europe
1,110,000,000 US dollars
Descovy - UNITED STATES
1,339,000,000 US dollars
Descovy - Rest of World
82,000,000 US dollars
Descovy - Europe
75,000,000 US dollars
Genvoya - UNITED STATES
1,088,000,000 US dollars
Genvoya - Rest of World
66,000,000 US dollars
Genvoya - Europe
138,000,000 US dollars
Odefsey - UNITED STATES
705,000,000 US dollars
Odefsey - Rest of World
30,000,000 US dollars
Odefsey - Europe
217,000,000 US dollars
Other HIV - UNITED STATES
190,000,000 US dollars
Other HIV - Rest of World
36,000,000 US dollars
Other HIV - Europe
96,000,000 US dollars
Symtuza - Revenue share - UNITED STATES
338,000,000 US dollars
Symtuza - Revenue share - Rest of World
9,000,000 US dollars
Symtuza - Revenue share - Europe
101,000,000 US dollars
Total Liver Disease - UNITED STATES
1,210,000,000 US dollars
Total Liver Disease - Rest of World
682,000,000 US dollars
Total Liver Disease - Europe
411,000,000 US dollars
Other Liver Disease - UNITED STATES
134,000,000 US dollars
Other Liver Disease - Rest of World
55,000,000 US dollars
Other Liver Disease - Europe
148,000,000 US dollars
Sofosbuvir/Velpatasvir - UNITED STATES
737,000,000 US dollars
Sofosbuvir/Velpatasvir - Rest of World
299,000,000 US dollars
Sofosbuvir/Velpatasvir - Europe
230,000,000 US dollars
Vemlidy - UNITED STATES
338,000,000 US dollars
Vemlidy - Rest of World
328,000,000 US dollars
Vemlidy - Europe
33,000,000 US dollars
Total Oncology - UNITED STATES
1,338,000,000 US dollars
Total Oncology - Rest of World
280,000,000 US dollars
Total Oncology - Europe
828,000,000 US dollars
AmBisome - UNITED STATES
37,000,000 US dollars
AmBisome - Rest of World
176,000,000 US dollars
AmBisome - Europe
210,000,000 US dollars
Other - UNITED STATES
203,000,000 US dollars
Other - Rest of World
52,000,000 US dollars
Other - Europe
26,000,000 US dollars
Total Other - UNITED STATES
241,000,000 US dollars
Total Other - Rest of World
228,000,000 US dollars
Total Other - Europe
236,000,000 US dollars
Royalty, contract and other revenues - UNITED STATES
66,000,000 US dollars
Royalty, contract and other revenues - Rest of World
2,000,000 US dollars
Royalty, contract and other revenues - Europe
43,000,000 US dollars
Trodelvy - UNITED STATES
655,000,000 US dollars
Trodelvy - Rest of World
88,000,000 US dollars
Trodelvy - Europe
217,000,000 US dollars
Veklury - UNITED STATES
784,000,000 US dollars
Veklury - Rest of World
473,000,000 US dollars
Veklury - Europe
204,000,000 US dollars
Product sales - UNITED STATES
14,958,000,000 US dollars
Product sales - Rest of World
2,700,000,000 US dollars
Product sales - Europe
3,416,000,000 US dollars
Selling, general and administrative expenses
4,184,000,000 US dollars. Source detail retained; this breakdown has not reconciled exactly and is not drawn.
Acquired in-process research and development expenses
4,674,000,000 US dollars. Source detail retained; this breakdown has not reconciled exactly and is not drawn.
Research and development expenses
4,266,000,000 US dollars. Source detail retained; this breakdown has not reconciled exactly and is not drawn.
In-process research and development impairment
4,180,000,000 US dollars. Source detail retained; this breakdown has not reconciled exactly and is not drawn.
Revenue before reconciliation (calculated)
63,359,000,000 US dollars. Sum of the reported revenue categories before the separately reported reconciliation.
Components above reported revenue (calculated)
negative 42,174,000,000 US dollars. The disclosed components add up to more than reported revenue; this is the difference, calculated, not a reported item.

Chart connections

  • Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
  • Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.
  • Reported revenue categories plus the separately reported signed reconciliation equals consolidated revenue.
GILEAD SCIENCES, INC. (GILD) FY2024 YTD Q3 P&L / Income Statement Sankey chart, Product and service — Product and Service by Geographical view
Free to share unchanged, with credit to Plicit.ai · CC BY-NC-ND 4.0Download PNG

Gross margin

78.0%

Gross profit / revenue

Operating margin

−3.7%

Operating profit / revenue

Newsletter

Get the teardowns by email

Subscribe if you want the public-company teardowns in your inbox when they're released.

Product waitlist

Health Check and Teardown for your own company

A health check uncovers insights of your private books, not a public ticker. Join this list to get notified as soon as we go-live!